Cargando…

Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update

Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by dysregulation of the immune system, vascular damage, and fibrosis of the skin and internal organs. Patients with SSc show a heterogeneous phenotype and a range of clinical courses. Therefore, biomarkers that are helpful for pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Utsunomiya, Akira, Oyama, Noritaka, Hasegawa, Minoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690387/
https://www.ncbi.nlm.nih.gov/pubmed/33105647
http://dx.doi.org/10.3390/jcm9113388
_version_ 1783614056183103488
author Utsunomiya, Akira
Oyama, Noritaka
Hasegawa, Minoru
author_facet Utsunomiya, Akira
Oyama, Noritaka
Hasegawa, Minoru
author_sort Utsunomiya, Akira
collection PubMed
description Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by dysregulation of the immune system, vascular damage, and fibrosis of the skin and internal organs. Patients with SSc show a heterogeneous phenotype and a range of clinical courses. Therefore, biomarkers that are helpful for precise diagnosis, prediction of clinical course, and evaluation of the therapeutic responsiveness of disease are required in clinical practice. SSc-specific autoantibodies are currently used for diagnosis and prediction of clinical features, as other biomarkers have not yet been fully vetted. Krebs von den Lungen-6 (KL-6), surfactant protein-D (SP-D), and CCL18 have been considered as serum biomarkers of SSc-related interstitial lung disease. Moreover, levels of circulating brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) can provide diagnostic information and indicate the severity of pulmonary arterial hypertension. Assessment of several serum/plasma cytokines, chemokines, growth factors, adhesion molecules, and other molecules may also reflect the activity or progression of fibrosis and vascular involvement in affected organs. Recently, microRNAs have also been implicated as possible circulating indicators of SSc. In this review, we focus on several potential SSc biomarkers and discuss their clinical utility.
format Online
Article
Text
id pubmed-7690387
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76903872020-11-27 Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update Utsunomiya, Akira Oyama, Noritaka Hasegawa, Minoru J Clin Med Review Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by dysregulation of the immune system, vascular damage, and fibrosis of the skin and internal organs. Patients with SSc show a heterogeneous phenotype and a range of clinical courses. Therefore, biomarkers that are helpful for precise diagnosis, prediction of clinical course, and evaluation of the therapeutic responsiveness of disease are required in clinical practice. SSc-specific autoantibodies are currently used for diagnosis and prediction of clinical features, as other biomarkers have not yet been fully vetted. Krebs von den Lungen-6 (KL-6), surfactant protein-D (SP-D), and CCL18 have been considered as serum biomarkers of SSc-related interstitial lung disease. Moreover, levels of circulating brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) can provide diagnostic information and indicate the severity of pulmonary arterial hypertension. Assessment of several serum/plasma cytokines, chemokines, growth factors, adhesion molecules, and other molecules may also reflect the activity or progression of fibrosis and vascular involvement in affected organs. Recently, microRNAs have also been implicated as possible circulating indicators of SSc. In this review, we focus on several potential SSc biomarkers and discuss their clinical utility. MDPI 2020-10-22 /pmc/articles/PMC7690387/ /pubmed/33105647 http://dx.doi.org/10.3390/jcm9113388 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Utsunomiya, Akira
Oyama, Noritaka
Hasegawa, Minoru
Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update
title Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update
title_full Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update
title_fullStr Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update
title_full_unstemmed Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update
title_short Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update
title_sort potential biomarkers in systemic sclerosis: a literature review and update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690387/
https://www.ncbi.nlm.nih.gov/pubmed/33105647
http://dx.doi.org/10.3390/jcm9113388
work_keys_str_mv AT utsunomiyaakira potentialbiomarkersinsystemicsclerosisaliteraturereviewandupdate
AT oyamanoritaka potentialbiomarkersinsystemicsclerosisaliteraturereviewandupdate
AT hasegawaminoru potentialbiomarkersinsystemicsclerosisaliteraturereviewandupdate